BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 20462455)

  • 1. Differential CARM1 expression in prostate and colorectal cancers.
    Kim YR; Lee BK; Park RY; Nguyen NT; Bae JA; Kwon DD; Jung C
    BMC Cancer; 2010 May; 10():197. PubMed ID: 20462455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability.
    Majumder S; Liu Y; Ford OH; Mohler JL; Whang YE
    Prostate; 2006 Sep; 66(12):1292-301. PubMed ID: 16705743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status.
    Hong H; Kao C; Jeng MH; Eble JN; Koch MO; Gardner TA; Zhang S; Li L; Pan CX; Hu Z; MacLennan GT; Cheng L
    Cancer; 2004 Jul; 101(1):83-9. PubMed ID: 15221992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer.
    Clark EL; Coulson A; Dalgliesh C; Rajan P; Nicol SM; Fleming S; Heer R; Gaughan L; Leung HY; Elliott DJ; Fuller-Pace FV; Robson CN
    Cancer Res; 2008 Oct; 68(19):7938-46. PubMed ID: 18829551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
    Deng X; Shao G; Zhang HT; Li C; Zhang D; Cheng L; Elzey BD; Pili R; Ratliff TL; Huang J; Hu CD
    Oncogene; 2017 Mar; 36(9):1223-1231. PubMed ID: 27546619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells.
    Cinar B; Yeung F; Konaka H; Mayo MW; Freeman MR; Zhau HE; Chung LW
    Biochem J; 2004 Apr; 379(Pt 2):421-31. PubMed ID: 14715080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A coactivator role of CARM1 in the dysregulation of β-catenin activity in colorectal cancer cell growth and gene expression.
    Ou CY; LaBonte MJ; Manegold PC; So AY; Ianculescu I; Gerke DS; Yamamoto KR; Ladner RD; Kahn M; Kim JH; Stallcup MR
    Mol Cancer Res; 2011 May; 9(5):660-70. PubMed ID: 21478268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.
    Yuan X; Li T; Wang H; Zhang T; Barua M; Borgesi RA; Bubley GJ; Lu ML; Balk SP
    Am J Pathol; 2006 Aug; 169(2):682-96. PubMed ID: 16877366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation-mediated abrogation of androgen signaling: an in vitro model of prostate cell inflammation.
    Debelec-Butuner B; Alapinar C; Varisli L; Erbaykent-Tepedelen B; Hamid SM; Gonen-Korkmaz C; Korkmaz KS
    Mol Carcinog; 2014 Feb; 53(2):85-97. PubMed ID: 22911881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purification and identification of a novel complex which is involved in androgen receptor-dependent transcription.
    Hosohata K; Li P; Hosohata Y; Qin J; Roeder RG; Wang Z
    Mol Cell Biol; 2003 Oct; 23(19):7019-29. PubMed ID: 12972618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arginine methyltransferase CARM1 is a promoter-specific regulator of NF-kappaB-dependent gene expression.
    Covic M; Hassa PO; Saccani S; Buerki C; Meier NI; Lombardi C; Imhof R; Bedford MT; Natoli G; Hottiger MO
    EMBO J; 2005 Jan; 24(1):85-96. PubMed ID: 15616592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
    Axlund SD; Lambert JR; Nordeen SK
    Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells.
    Dai JL; Maiorino CA; Gkonos PJ; Burnstein KL
    Steroids; 1996 Sep; 61(9):531-9. PubMed ID: 8883219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p68/DdX5 supports β-catenin & RNAP II during androgen receptor mediated transcription in prostate cancer.
    Clark EL; Hadjimichael C; Temperley R; Barnard A; Fuller-Pace FV; Robson CN
    PLoS One; 2013; 8(1):e54150. PubMed ID: 23349811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXM1 promotes the progression of prostate cancer by regulating PSA gene transcription.
    Liu Y; Liu Y; Yuan B; Yin L; Peng Y; Yu X; Zhou W; Gong Z; Liu J; He L; Li X
    Oncotarget; 2017 Mar; 8(10):17027-17037. PubMed ID: 28199985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progression.
    Grypari IM; Logotheti S; Zolota V; Troncoso P; Efstathiou E; Bravou V; Melachrinou M; Logothetis C; Tzelepi V
    Medicine (Baltimore); 2021 Sep; 100(36):e27094. PubMed ID: 34516499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
    Paliouras M; Diamandis EP
    Biol Chem; 2008 Jun; 389(6):773-80. PubMed ID: 18627304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer.
    Ha S; Iqbal NJ; Mita P; Ruoff R; Gerald WL; Lepor H; Taneja SS; Lee P; Melamed J; Garabedian MJ; Logan SK
    Oncogene; 2013 Aug; 32(34):3992-4000. PubMed ID: 22986532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.
    Guo Z; Yang X; Sun F; Jiang R; Linn DE; Chen H; Chen H; Kong X; Melamed J; Tepper CG; Kung HJ; Brodie AM; Edwards J; Qiu Y
    Cancer Res; 2009 Mar; 69(6):2305-13. PubMed ID: 19244107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
    Cai Y; Lee YF; Li G; Liu S; Bao BY; Huang J; Hsu CL; Chang C
    Int J Cancer; 2008 Jul; 123(1):195-201. PubMed ID: 18386814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.